1. Oncolytic virotherapy improves immunotherapies targeting cancer stemness in glioblastoma.
- Author
-
Keshavarz M, Dianat-Moghadam H, Ghorbanhosseini SS, and Sarshari B
- Subjects
- Humans, Brain Neoplasms therapy, Brain Neoplasms immunology, Brain Neoplasms pathology, Oncolytic Viruses immunology, Animals, Oncolytic Virotherapy methods, Glioblastoma therapy, Glioblastoma immunology, Glioblastoma pathology, Neoplastic Stem Cells immunology, Neoplastic Stem Cells pathology, Immunotherapy methods, Tumor Microenvironment immunology
- Abstract
Despite advances in cancer therapies, glioblastoma (GBM) remains the most resistant and recurrent tumor in the central nervous system. GBM tumor microenvironment (TME) is a highly dynamic landscape consistent with alteration in tumor infiltration cells, playing a critical role in tumor progression and invasion. In addition, glioma stem cells (GSCs) with self-renewal capability promote tumor recurrence and induce therapy resistance, which all have complicated eradication of GBM with existing therapies. Oncolytic virotherapy is a promising field of therapy that can kill tumor cells in a targeted manner. Manipulated oncolytic viruses (OVs) improve cancer immunotherapy by directly lysis tumor cells, infiltrating antitumor cells, inducing immunogenic cell death, and sensitizing immune-resistant TME to an immune-responsive hot state. Importantly, OVs can target stemness-driven GBM progression. In this review, we will discuss how OVs as a therapeutic option target GBM, especially the GSC subpopulation, and induce immunogenicity to remodel the TME, which subsequently enhances immunotherapies' efficiency., Competing Interests: Declaration of competing interest The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF